Cycloalkylamines as monoamine reuptake inhibitors
US10562878B2 · kind B2 · utility
0Cited by
39References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 8, 2017 |
| Grant date | Feb 18, 2020 |
| Priority date | — |
| Expiry date | Dec 8, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.